Amili, a Singapore-based precision gut microbiome startup, has raised $10.5 million in Series A funding.
This round was led by Vulcan Capital, the investment arm of late Microsoft Corp Co-Founder Paul Allen, which invests in category-leading technology, internet, and life sciences firms.
Pruksa Group, TVM Capital Healthcare, Emtek Group, Capital Code, Pureland Group, Blue7, GK Goh, and SEEDS Capital were among the companies that took part.
Amili plans to use the funds to expand its business in Southeast and Greater Asia. The funding will also be utilized to create Amili Prime and accelerate microbiome research partnerships and discovery.
Amili has three products: a multi-ethnic Asia microbiome database, a microbiome bank containing samples for metagenomic and metabolomic study, and Amili Prime, a suite of unique analytical tools, informatics pipelines, and discovery engines.
The firm’s four commercial engines are powered by their fundamental assets which include diagnostics and therapeutics, collection, analysis, and faecal microbiota transplant, personalized wellness, and food for health.
Trillions of bacteria, viruses, and fungus live in the digestive tract, making up the gut microbiome. It is involved in nearly every area of human health.
The company claims to have established more than 20 research studies across a wide spectrum of health indications since its founding, with a total grant value of more than S$60 million.
In 2022, the company expects to grow its BIO & ME product across Southeast Asia and Hong Kong.
Amili collaborates collaboratively with academic institutions and biotech firms to discover new biomarkers, uncover mechanistic processes, and develop products to alter the gut microbiome and treat disease.
The Singaporean startup collaborates with food makers and merchants to help them validate, measure, and develop their products. Amili gives customers information about the influence of various components, recipes, and foods on the human microbiome, with a focus on Asian consumers.